Creating cell lines with future manufacturability, cost of goods and speed in mind is of critical importance. How can time to the clinic be reduced and yet a drug candidate be equipped with a robust CMC-package from day one?
Join Jennifer Peuchot, Group Leader in the Cell Culture Development team at Lonza Biologics to learn how you can chart an optimal path from gene to the clinic by tailoring your cell line development program to match your molecule type, timelines, yield requirements and risk priorities.
Backed by case studies, we will discuss
- How to effectively combine host cell line, vector and stringency of selection to develop high producing cell lines suited to fit a commercially relevant platform process.
- How to quickly and reliably express new molecular formats and achieve appropriate product characteristic profile
- How to accelerate your path to tox drug product and to the clinic while minimizing risk